AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00295490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo has same dosing freq as for active intervention and for same time period
Trial: NCT02353936
Drug: BIBW2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily
Trial: NCT00223093
Drug: TAIZ
RxNorm normalized name: ALCOHOL 400 mL in 500 mL TOPICAL LIQUID [Miracle Power Hand Sanitaizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00406393
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
Trial: NCT01983735
Drug: TELMINUVO Tab. (80/2.5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~* With the others investigation product placebo 1 tab QD 2 weeks.
Trial: NCT01983735
Drug: TELMINUVO Tab. (80/5mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~* With the others investigation product placebo 1 tab QD 6 weeks.
Trial: NCT01022190
Drug: Etoricoxib (Arcoxia)
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
Trial: NCT00244023
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
Trial: NCT00244023
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
Trial: NCT02426450
Drug: 5-Fluorouracil/Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Trial: NCT01640743
Drug: Tacrolimus + Methylprednisolone
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Trial: NCT04418765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concentrate for solution for infusion, intravenously
Trial: NCT01640743
Drug: Tacrolimus + Everolimus + Methylprednisolone
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Trial: NCT04797936
Drug: BNO 1030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imupret 25 drops х 6 times per day for 14 days
Trial: NCT03130790
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Trial: NCT03130790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Trial: NCT00341250
Drug: AMA1-C1/Alhydrogel Malaria Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01077973
Drug: Novel Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
Trial: NCT01077973
Drug: Standard Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of standard ibuprofen (400mg) plus placebo
Trial: NCT01077973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo
Trial: NCT00415779
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg IV every 2 weeks
Trial: NCT04090658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects aged 60 to 80 years received 2 doses of placebo as control, at Day 1 and Day 61, by IM injection into the deltoid region of the non-dominant arm preferably.
Trial: NCT00080782
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral celecoxib twice daily in the absence of disease progression.
Trial: NCT00080782
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By vein (IV) over 30 minutes on days 1, 8, 15, and 22
Trial: NCT01392820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, twice daily
Trial: NCT02364986
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif® 44µg (day 1, 3, 5 and 8) s.c.
Trial: NCT02517424
Drug: High THC/Low CBD Cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cannabis
Trial: NCT02517424
Drug: Low THC/Low CBD Cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cannabis
Trial: NCT00901719
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
Trial: NCT00314106
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/ day x 2 days intravenous
Trial: NCT03485118
Drug: HS006+CHOP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug:HS006 HS006 375 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.
Trial: NCT03485118
Drug: HS006+CHOP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug:HS006 HS006 500 mg per square meter (mg/m\^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m\^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle.
Trial: NCT01975545
Drug: Fluor varnish
RxNorm normalized name: Fluor a Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental varnish will be applied to one anterior superior teeth in a random side.
Trial: NCT01975545
Drug: Fluor varnish with nanoparticles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
Trial: NCT04479800
Drug: ASTX660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: capsule; Route of administration: oral
Trial: NCT02956993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03175549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo pills taken orally for 14 days
Trial: NCT00208091
Drug: Botulinum toxin, type B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
Trial: NCT00022087
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
Trial: NCT01559116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tiotropium+olodaterol FDC
Trial: NCT00562718
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06259630
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant receives oral dose of placebo
Trial: NCT02057406
Drug: 2:1 EPA/DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
Trial: NCT01627431
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg once per day
Trial: NCT03277248
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03277248
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV Infusion.
Trial: NCT03720548
Drug: LY3372993
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00302471
Drug: Comparator: MK0429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease.
Trial: NCT00302471
Drug: Comparator: MK0429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Trial: NCT00302471
Drug: Comparator: MK0429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Trial: NCT00302471
Drug: Comparator: MK0429
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Trial: NCT03720548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00931398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for all Concerta doses.
Trial: NCT01200186
Drug: EV/DNG (Qlaira, BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the discretion of the attending physician
Trial: NCT01200186
Drug: Progestin Only Pills
RxNorm normalized name: Prostin E2 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the discretion of the attending physician
Trial: NCT04184947
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prescription of a GLP-1 receptor agonisty (exenatide, liraglutide, lixisenatide, dulaglutide) at any dosage during routine clinical practice
Trial: NCT01167335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00756860
Drug: Renagel® (sevelamer hydrochloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
Trial: NCT02589067
Drug: Saline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
Trial: NCT01574027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule per day for six months
Trial: NCT01514929
Drug: ACHN-490 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg IV 30 minute infusion given once
Trial: NCT01472887
Drug: SAR3419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous
Trial: NCT01514929
Drug: ACHN-490 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg IV 30 minute infusion given once
Trial: NCT01514929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral pill given once
Trial: NCT01426854
Drug: Nepafenac Ophthalmic Suspension, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular administration
Trial: NCT03929016
Drug: DNDI-0690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules of 10, 100 and 200 mg
Trial: NCT03929016
Drug: Placebo of DNDI-0690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules of matching placebo
Trial: NCT01710696
Drug: 17-beta estradiol
RxNorm normalized name: 17-beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
Trial: NCT00757419
Drug: AZD3355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, oral, single or twice daily dose
Trial: NCT00757419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To match dosing of AZD3355
Trial: NCT00950300
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Trial: NCT01656434
Drug: NOMAC-E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
Trial: NCT04315896
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT04128540
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
Trial: NCT01604239
Drug: Shinbaro Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg twice a day (b.i.d) oral herbal medicine
Trial: NCT01693809
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02692716
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral use once daily.
Trial: NCT04039815
Drug: Ascorbic acid-Vitamin B1-Hydrocortisone
RxNorm normalized name: ascorbic acid / vitamin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
Trial: NCT04039815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
Trial: NCT03074591
Drug: Ferric Carboxymaltose 50Mg/Ml Inj 15Ml
RxNorm normalized name: FERRIC CARBOXYMALTOSE 50MG/ML INJ 15ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
Trial: NCT03074591
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
Trial: NCT01948622
Drug: Mulungu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/single dose/1 hour before dental surgery
Trial: NCT01948622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/single dose/1 hour before dental surgery
Trial: NCT02131220
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracoronary bolus infusion using selective catheter during PCI
Trial: NCT03521934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT01490190
Drug: Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)
RxNorm normalized name: ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
Trial: NCT00337493
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentration-controlled
Trial: NCT00337493
Drug: mycophenolate mofetil [CellCept]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g po bid
Trial: NCT02455232
Drug: 4cc of lidocaïne®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04107194
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT04107194
Drug: Tetracycline 125 MG
RxNorm normalized name: tetracycline 125 MG
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT00483743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 caps BID x42 days
Trial: NCT00301886
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01257984
Drug: BAY86-5300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
Trial: NCT01257984
Drug: BAY86-5300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
Trial: NCT00516295
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04378608
Drug: OBV/PTV/r) ± ribavirin (RBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04459754
Drug: Fuzheng Yiliu Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption.
Trial: NCT01218204
Drug: GSK1292263 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01218204
Drug: 100mg GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg
Trial: NCT01218204
Drug: 300mg GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg
Trial: NCT01218204
Drug: 800mg GSK1292263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg